Chimeric Therapeutics Ltd.

Chimeric Therapeutics, is developing new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy against solid tumours.

Chimeric Therapeutics is jointly established by The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK. The company is aimed at translating an academic discovery programme funded by Cancer Research UK and developed by Dr Steven Lee and Prof Roy Bicknell at the University of Birmingham into a commercially viable cell therapy.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
12th Floor Tower Wing Guys Hospital,Great Maze Pond,SE1 9RT
London
United Kingdom
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/chimeric-therapeutics-limited” connections=”true” suffix=””]

The company is developing new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy for solid tumours, by directing the CAR-T cell towards a new, highly specific marker of tumour angiogenesis, CLEC14a. This therapy will act as a vasculature disruptive agent compromising oxygen supply to the tumours and inhibiting tumour growth. The technology is currently undergoing the final stages of preclinical development, and is planned to enter into clinical trials soon after.